Elly Gerald Stoica

Array ( [id] => 18207624 [patent_doc_number] => 20230053881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => NEUREGULIN FOR THE TREATMENT AND/OR PREVENTION OF TUMORS OF THE NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 17/878221 [patent_app_country] => US [patent_app_date] => 2022-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17878221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20328381 [patent_doc_number] => 12458638 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Method of stimulating neutrophil survival and reducing neutropenia [patent_app_type] => utility [patent_app_number] => 17/877198 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19434 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17877198 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20607096 [patent_doc_number] => 12582675 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-24 [patent_title] => Methods for treatment of cancers harboring an H3K27M mutation [patent_app_type] => utility [patent_app_number] => 17/815056 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 54 [patent_no_of_words] => 18467 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18197885 [patent_doc_number] => 20230051404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => IMMUNOGENIC COMPOSITIONS COMPRISING NUCLEIC ACIDS FOR RAS PEPTIDES [patent_app_type] => utility [patent_app_number] => 17/815086 [patent_app_country] => US [patent_app_date] => 2022-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20262971 [patent_doc_number] => 12433939 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Self-assembling synthetic proteins comprising cholera toxin beta subunit [patent_app_type] => utility [patent_app_number] => 17/862952 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 17 [patent_no_of_words] => 5800 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19140529 [patent_doc_number] => 20240139321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => UNIVERSAL CAR-T CELL TARGETING GD2, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/575451 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18575451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448983 [patent_doc_number] => 20240309113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => NOVEL ANTI-MASP-2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/575326 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18575326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360844 [patent_doc_number] => 20240262878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => PHOTOACTIVATABLE GASDERMIN PROTEINS [patent_app_type] => utility [patent_app_number] => 18/567159 [patent_app_country] => US [patent_app_date] => 2022-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18567159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961634 [patent_doc_number] => 12331118 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Humanized anti-human-PD-1 antibody and methods of using them for cancer treatment [patent_app_type] => utility [patent_app_number] => 17/830381 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 26844 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17830381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360886 [patent_doc_number] => 20240262920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => DOSING REGIMENS FOR PROTEIN THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 18/562725 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45167 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -93 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20480395 [patent_doc_number] => 12528866 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Recombinant protein targeting PD-L1 and VEGF and compositions thereof [patent_app_type] => utility [patent_app_number] => 17/737159 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 5383 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17737159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20316151 [patent_doc_number] => 12454695 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-28 [patent_title] => Fusion polypeptides comprising interleukin 12 and a metal-hydroxide binding polypeptide [patent_app_type] => utility [patent_app_number] => 17/736431 [patent_app_country] => US [patent_app_date] => 2022-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 32178 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17736431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18634937 [patent_doc_number] => 11759508 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-19 [patent_title] => Antigenic peptides for treatment of B-cell malignancy [patent_app_type] => utility [patent_app_number] => 17/734694 [patent_app_country] => US [patent_app_date] => 2022-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 22 [patent_no_of_words] => 45235 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17734694 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20882305 [patent_doc_number] => 12698336 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-04 [patent_title] => Anti-human CD73 monoclonal antibody without hook effect [patent_app_type] => utility [patent_app_number] => 18/031130 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 0 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828464 [patent_doc_number] => 20220265768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => METHODS OF BOOSTING THYMIC REGENERATION IN PATIENTS SUFFERING FROM A THYMIC INJURY BY USING RANKL [patent_app_type] => utility [patent_app_number] => 17/730261 [patent_app_country] => US [patent_app_date] => 2022-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17730261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19216321 [patent_doc_number] => 20240181025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => Antigen Presenting Polypeptide Complexes Bearing TGF-Beta and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 18/287747 [patent_app_country] => US [patent_app_date] => 2022-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72317 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 284 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545315 [patent_doc_number] => 11718655 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Masked interleukin-12 polypeptides [patent_app_type] => utility [patent_app_number] => 17/716873 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 132 [patent_no_of_words] => 157470 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17716873 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379311 [patent_doc_number] => 20240269181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => METHOD FOR REGENERATING HUMORAL IMMUNITY SYSTEM AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/562645 [patent_app_country] => US [patent_app_date] => 2022-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19258206 [patent_doc_number] => 12018252 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Methods and compositions for identifying neoantigens for use in treating cancer [patent_app_type] => utility [patent_app_number] => 17/711849 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 49 [patent_no_of_words] => 17391 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18559800 [patent_doc_number] => 11725034 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => IL2 agonists and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/709706 [patent_app_country] => US [patent_app_date] => 2022-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 132 [patent_no_of_words] => 51205 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709706 [rel_patent_id] =>[rel_patent_doc_number] =>)